Pigment Epithelium-Derived Factor as an Impending Therapeutic Agent Against Vascular Epithelial Growth Factor-Driven Tumor-Angiogenesis
MetadataShow full item record
In spite of the recent epidemiological study indicating a positive decrease in cancer trends, cancer remains to be one of the major causes of deaths and there is an anticipated increase in the number of new cancer cases to be recorded in the following years to come. It is important for researchers to improve the current therapeutic agents involved against cancer, particularly targeting to inhibit tumor cell growth, survival, and metastasis. Many researchers investigate the crucial role of a proangiogenic factor, vascular endothelial growth factor (VEGF) in the process of tumor angiogenesis, where the formation of new blood vessels carrying essential nutrients to the tumor cell becomes a critical factor for tumor growth. Since the establishment of VEGF's integral role in mediating tumor angiogenesis and tumor cell survival, current efforts are dedicated to developing therapeutic agents against VEGF and one of the emerging candidate under this category is pigment epithelium-derived factor (PEDF).
Showing items related by title, author, creator and subject.
Shanmugam, M.; Warrier, S.; Kumar, A.; Sethi, G.; Arfuso, Frank (2017)BACKGROUND: Neovascularization, also known as angiogenesis, is the process of capillary sprouting from pre-existing blood vessels. This physiological process is a hallmark event in normal embryonic development as blood ...
Rapid copper acquisition by developing murine mesothelioma: Decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltrationCrowe, Andrew; Jackaman, Connie; Beddoes, Katie; Ricciardo, Belinda; Nelson, Delia (2013)Copper, an essential trace element acquired through nutrition, is an important co-factor for pro-angiogenic factors including vascular endothelial growth factor (VEGF). Decreasing bioavailable copper has been used as an ...
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic featuresYe, L.; Leslie, C.; Jacques, Angela; Mesbah Ardakani, N.; Amanuel, B.; Millward, M. (2018)© 2018, United States & Canadian Academy of Pathology. Immune checkpoint inhibition is an important therapeutic option in patients with non-small cell lung cancer. Programmed cell death ligand-1 (PD-L1) expression may ...